Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CANbridge Pharmaceuticals Inc. ( (HK:1228) ) just unveiled an announcement.
CANbridge Pharmaceuticals Inc. has announced the appointment of Ms. Zhao Wei as a non-executive director and a member of the remuneration committee, effective June 30, 2025. This appointment is part of a broader change in the composition of the board committees, which also includes the addition of Dr. Lan Hu to the Nomination and Corporate Governance Committee to meet gender diversity requirements. These changes are expected to enhance the company’s governance and strategic direction.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for rare diseases and targeted oncology. The company aims to address unmet medical needs in these specialized markets.
Average Trading Volume: 5,299,196
Technical Sentiment Signal: Sell
Current Market Cap: HK$119M
See more insights into 1228 stock on TipRanks’ Stock Analysis page.